GeneDx (WGS) Competitors $129.19 +2.94 (+2.33%) Closing price 04:00 PM EasternExtended Trading$127.50 -1.69 (-1.31%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock WGS vs. HIMS, GH, RDNT, OPCH, SHC, BTSG, SGRY, CON, PRVA, and HTFLShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Hims & Hers Health (HIMS), Guardant Health (GH), RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), and Heartflow (HTFL). These companies are all part of the "healthcare" industry. GeneDx vs. Its Competitors Hims & Hers Health Guardant Health RadNet Option Care Health Sotera Health BrightSpring Health Services Surgery Partners Concentra Group Holdings Parent Privia Health Group Heartflow Hims & Hers Health (NYSE:HIMS) and GeneDx (NASDAQ:WGS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Does the media prefer HIMS or WGS? In the previous week, Hims & Hers Health had 49 more articles in the media than GeneDx. MarketBeat recorded 70 mentions for Hims & Hers Health and 21 mentions for GeneDx. GeneDx's average media sentiment score of 1.20 beat Hims & Hers Health's score of 0.31 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 16 Very Positive mention(s) 6 Positive mention(s) 41 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral GeneDx 14 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, HIMS or WGS? Hims & Hers Health has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Do analysts recommend HIMS or WGS? Hims & Hers Health presently has a consensus price target of $38.92, suggesting a potential downside of 11.69%. GeneDx has a consensus price target of $101.63, suggesting a potential downside of 21.34%. Given Hims & Hers Health's higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hims & Hers Health 3 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92GeneDx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is HIMS or WGS more profitable? Hims & Hers Health has a net margin of 9.63% compared to GeneDx's net margin of 0.39%. Hims & Hers Health's return on equity of 26.26% beat GeneDx's return on equity.Company Net Margins Return on Equity Return on Assets Hims & Hers Health9.63% 26.26% 13.06% GeneDx 0.39%16.51%9.35% Which has better earnings and valuation, HIMS or WGS? Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHims & Hers Health$1.48B6.75$126.04M$0.8055.09GeneDx$362.32M10.24-$52.29M$0.052,583.80 Do insiders and institutionals have more ownership in HIMS or WGS? 63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by company insiders. Comparatively, 29.6% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryHims & Hers Health beats GeneDx on 10 of the 16 factors compared between the two stocks. Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.71B$7.69B$5.74B$9.78BDividend YieldN/A2.74%4.40%4.04%P/E Ratio2,583.8078.4530.8326.39Price / Sales10.2445.31382.9086.63Price / Cash119.1024.4437.7259.11Price / Book13.3921.9510.106.62Net Income-$52.29M$242.04M$3.26B$265.42M7 Day Performance7.40%0.59%3.90%3.58%1 Month Performance61.83%-0.47%3.73%0.46%1 Year Performance265.46%9.94%37.68%19.41% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx2.1336 of 5 stars$129.19+2.3%$101.63-21.3%+254.7%$3.71B$362.32M2,583.801,200Positive NewsHIMSHims & Hers Health2.7265 of 5 stars$43.48+3.1%$38.92-10.5%+183.6%$9.53B$1.48B54.341,637Trending NewsInsider TradeGHGuardant Health3.284 of 5 stars$58.50-0.1%$57.50-1.7%+137.2%$7.30B$739.02M-17.462,021Positive NewsRDNTRadNet3.2523 of 5 stars$68.64+1.0%$71.60+4.3%+8.3%$5.22B$1.91B-343.1811,021Positive NewsOPCHOption Care Health4.8447 of 5 stars$27.22-4.7%$35.75+31.3%-11.0%$4.63B$5.00B21.788,088Positive NewsHigh Trading VolumeSHCSotera Health1.5331 of 5 stars$16.30+0.9%$16.00-1.8%+5.0%$4.59B$1.10B203.783,000Positive NewsInsider TradeBTSGBrightSpring Health Services1.6882 of 5 stars$23.63+1.9%$25.67+8.6%+88.0%$4.11B$11.27B76.2335,000Positive NewsSGRYSurgery Partners2.9697 of 5 stars$23.84+2.8%$33.00+38.4%-30.2%$2.97B$3.11B-16.6715,000Positive NewsCONConcentra Group Holdings Parent2.2358 of 5 stars$23.16+0.8%$27.50+18.7%-3.3%$2.94B$1.90B19.4611,250News CoveragePositive NewsPRVAPrivia Health Group3.6727 of 5 stars$21.15-0.3%$28.00+32.4%+0.5%$2.60B$1.74B192.291,140Positive NewsHTFLHeartflowN/A$29.31-4.4%N/AN/A$2.49BN/A0.00699Positive News Related Companies and Tools Related Companies HIMS Competitors GH Competitors RDNT Competitors OPCH Competitors SHC Competitors BTSG Competitors SGRY Competitors CON Competitors PRVA Competitors HTFL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WGS) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access